A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical

Abstract

Despite their attractive properties, internal targeted alpha therapies using ^223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra²⁺ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra²⁺ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona, the connection to other targeting (bio)macromolecules is possible.